The DOI matches its Crossref record; 111 of the 111 references it cites were found in a registry or an index.
An Official American Thoracic Society Workshop Report: Use of Animal Models for the Preclinical Assessment of Potential Therapies for Pulmonary Fibrosis
Open accessAbstract
Numerous compounds have shown efficacy in limiting development of pulmonary fibrosis using animal models, yet few of these compounds have replicated these beneficial effects in clinical trials. Given the challenges associated with performing clinical trials in patients with idiopathic pulmonary fibrosis (IPF), it is imperative that preclinical data packages be robust in their analyses and interpretations to have the best chance of selecting promising drug candidates to advance to clinical trials. The American Thoracic Society has convened a group of experts in lung fibrosis to discuss and formalize recommendations for preclinical assessment of antifibrotic compounds. The panel considered three major themes (choice of animal, practical considerations of fibrosis modeling, and fibrotic endpoints for evaluation). Recognizing the need for practical considerations, we have taken a pragmatic approach. The consensus view is that use of the murine intratracheal bleomycin model in animals of both genders, using hydroxyproline measurements for collagen accumulation along with histologic assessments, is the best-characterized animal model available for preclinical testing. Testing of antifibrotic compounds in this model is recommended to occur after the acute inflammatory phase has subsided (generally after Day 7). Robust analyses may also include confirmatory studies in human IPF specimens and validation of results in a second system using in vivo or in vitro approaches. The panel also strongly encourages the publication of negative results to inform the lung fibrosis community. These recommendations are for preclinical therapeutic evaluation only and are not intended to dissuade development of emerging technologies to better understand IPF pathogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationImproving bioscience research reporting: The ARRIVE guidelines for reporting animal research
Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M., & Altman, D. G. (2010) · Journal of Pharmacology and Pharmacotherapeutics · doi:10.4103/0976-500x.72351 · Cited by 6,277
Junqueira, L. C. U., Bignolas, G., & Brentani, R. R. (1979) · The Histochemical Journal · doi:10.1007/bf01002772 · Cited by 2,574
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Self-citationMunger, J. S., Huang, X., Kawakatsu, H., Griffiths, M. J. D., Dalton, S. L., Wu, J., Pittet, J.-F., Kaminski, N., Garat, C., Matthay, M. A., et al. (1999) · Cell · doi:10.1016/s0092-8674(00)80545-0 · Cited by 2,076
Self-citationSelman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786
Self-citationKlinge, U., Park, J.-K., & Klosterhalfen, B. (2013) · Pathobiology · doi:10.1159/000348446 · Cited by 1,783
Simple method of estimating severity of pulmonary fibrosis on a numerical scale.
Ashcroft, T., Simpson, J. M., & Timbrell, V (1988) · Journal of Clinical Pathology · doi:10.1136/jcp.41.4.467 · Cited by 1,680
Rock, J. R., Barkauskas, C. E., Cronce, M. J., Xue, Y., Harris, J. R., Liang, J., Noble, P. W., & Hogan, B. L. M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1117988108 · Cited by 1,030
Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis
Wollin, L., Wex, E., Pautsch, A., Schnapp, G., Hostettler, K. E., Stowasser, S., & Kolb, M. (2015) · European Respiratory Journal · doi:10.1183/09031936.00174914 · Cited by 1,005
Self-citation
Cited by
Inhalation of lung spheroid cell secretome and exosomes promotes lung repair in pulmonary fibrosis
Dinh, P.-U. C., Paudel, D., Brochu, H., Popowski, K. D., Gracieux, M. C., Cores, J., Huang, K., Hensley, M. T., Harrell, E., Vandergriff, A. C., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14344-7 · Cited by 435
Lung Microbiota Contribute to Pulmonary Inflammation and Disease Progression in Pulmonary Fibrosis
O’Dwyer, D. N., Ashley, S. L., Gurczynski, S. J., Xia, M., Wilke, C., Falkowski, N. R., Norman, K. C., Arnold, K. B., Huffnagle, G. B., Salisbury, M. L., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201809-1650oc · Cited by 366
Self-citationInterleukin-11 is a therapeutic target in idiopathic pulmonary fibrosis
Ng, B., Dong, J., D’Agostino, G., Viswanathan, S., Widjaja, A. A., Lim, W.-W., Ko, N. S. J., Tan, J., Chothani, S. P., Huang, B., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw1237 · Cited by 314
Exploring Animal Models That Resemble Idiopathic Pulmonary Fibrosis
Tashiro, J., Rubio, G. A., Limper, A. H., Williams, K., Elliot, S. J., Ninou, I., Aidinis, V., Tzouvelekis, A., & Glassberg, M. K. (2017) · Frontiers in Medicine · doi:10.3389/fmed.2017.00118 · Cited by 314
Pakshir, P., Noskovicova, N., Lodyga, M., Son, D. O., Schuster, R., Goodwin, A., Karvonen, H., & Hinz, B. (2020) · Journal of Cell Science · doi:10.1242/jcs.227900 · Cited by 293
Wahab, A., Muhammad, M., Ullah, S., Abdi, G., Shah, G. M., Zaman, W., & Ayaz, A. (2024) · Science of The Total Environment · doi:10.1016/j.scitotenv.2024.171862 · Cited by 287
Osuchowski, M. F., Ayala, A., Bahrami, S., Bauer, M., Boros, M., Cavaillon, J.-M., Chaudry, I. H., Coopersmith, C. M., Deutschman, C. S., Drechsler, S., et al. (2018) · Shock · doi:10.1097/shk.0000000000001212 · Cited by 259
The mTORC1/4E-BP1 axis represents a critical signaling node during fibrogenesis
Woodcock, H. V., Eley, J. D., Guillotin, D., Platé, M., Nanthakumar, C. B., Martufi, M., Peace, S., Joberty, G., Poeckel, D., Good, R. B., et al. (2019) · Nature Communications · doi:10.1038/s41467-018-07858-8 · Cited by 224
Self-citationUse of precision cut lung slices as a translational model for the study of lung biology
Liu, G., Betts, C., Cunoosamy, D. M., Åberg, P. M., Hornberg, J. J., Sivars, K. B., & Cohen, T. S. (2019) · Respiratory Research · doi:10.1186/s12931-019-1131-x · Cited by 206
Lodyga, M., Cambridge, E., Karvonen, H. M., Pakshir, P., Wu, B., Boo, S., Kiebalo, M., Kaarteenaho, R., Glogauer, M., Kapoor, M., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aao3469 · Cited by 181
Inui, N., Sakai, S., & Kitagawa, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116107 · Cited by 169
Multipotent stromal cells: One name, multiple identities
Soliman, H., Theret, M., Scott, W., Hill, L., Underhill, T. M., Hinz, B., & Rossi, F. M. V. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.09.001 · Cited by 147
PAD4 deficiency improves bleomycin-induced neutrophil extracellular traps and fibrosis in mouse lung
Suzuki, M., Ikari, J., Anazawa, R., Tanaka, N., Katsumata, Y., Shimada, A., Suzuki, E., & Tatsumi, K. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0433oc · Cited by 143
Herrmann, F. E., Hesslinger, C., Wollin, L., & Nickolaus, P. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.838449 · Cited by 137
“Despite these restrictions, the bleomycin model is still a good tool to assess the efficacy of potential compounds in general as proof of principle (Moeller et al., 2008; Jenkins et al., 2017).”
BackgroundInfluentialJohn, A. E., Graves, R. H., Pun, K. T., Vitulli, G., Forty, E. J., Mercer, P. F., Morrell, J. L., Barrett, J. W., Rogers, R. F., Hafeji, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18397-6 · Cited by 131
Self-citationCaveolin-1–derived peptide limits development of pulmonary fibrosis
Marudamuthu, A. S., Bhandary, Y. P., Fan, L., Radhakrishnan, V., MacKenzie, B., Maier, E., Shetty, S. K., Nagaraja, M. R., Gopu, V., Tiwari, N., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aat2848 · Cited by 86
Ezzo, M., Spindler, K., Wang, J. B., Lee, D., Pecoraro, G., Cowen, J., Pakshir, P., & Hinz, B. (2024) · Science Advances · doi:10.1126/sciadv.adp4726 · Cited by 82
“Wild-type male C57BL/6 J mice at 8 to 12 weeks of age were used according to the current guidelines by the American Thoracic Society ( 79 ).”
MethodInvariant natural killer T cells coordinate removal of senescent cells
Arora, S., Thompson, P. J., Wang, Y., Bhattacharyya, A., Apostolopoulou, H., Hatano, R., Naikawadi, R. P., Shah, A., Wolters, P. J., Koliwad, S., et al. (2021) · Med · doi:10.1016/j.medj.2021.04.014 · Cited by 77
Screening for YAP inhibitors identifies statins as modulators of fibrosis
Santos, D. M., Pantano, L., Pronzati, G., Grasberger, P., Probst, C. K., Black, K. E., Spinney, J. J., Hariri, L. P., Nichols, R., Lin, Y., et al. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0296oc · Cited by 72
Self-citationYan, J., Wang, S.-Y., Su, Q., Zou, M.-W., Zhou, Z.-Y., Shou, J., & Huo, Y. (2025) · Nature Communications · doi:10.1038/s41467-025-59093-7 · Cited by 62
Chen, Y., Wang, T., Liang, F., Han, J., Lou, Z., Yu, Y., Li, J., Zhan, T., Gu, Y., Dong, L., et al. (2024) · Theranostics · doi:10.7150/thno.94482 · Cited by 60
“We further induced lung fibrosis in mice by intratracheal injection of bleomycin (BLM, 3 mg/kg), according to the previous report [37].”
MethodA novel phosphodiesterase 4 inhibitor, AA6216, reduces macrophage activity and fibrosis in the lung
Matsuhira, T., Nishiyama, O., Tabata, Y., Kaji, C., Kubota-Ishida, N., Chiba, Y., Sano, H., Iwanaga, T., & Tohda, Y. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173508 · Cited by 41
Metadata
- Authors
- Jenkins, R. G., Moore, B. B., Chambers, R. C., Eickelberg, O., Königshoff, M., Kolb, M., Laurent, G. J., Nanthakumar, C. B., Olman, M. A., Pardo, A., Selman, M., Sheppard, D., Sime, P. J., Tager, A. M., Tatler, A. L., Thannickal, V. J., & White, E. S.
- Venue
- American Journal of Respiratory Cell and Molecular Biology
- Publisher
- Oxford University Press (OUP)
- Published
- 2017-05-01
- Volume
- 56
- Issue
- 5
- Pages
- 667-679
- ISSN
- 1044-1549 (ISSN-L)
- 1535-4989
- OpenAlex
- W2610199736
- Cited by
- 435
- References
- 111
- FWCI
- 21.67
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.